Skip to main content
. Author manuscript; available in PMC: 2014 Aug 8.
Published in final edited form as: Sci Transl Med. 2010 Dec 22;2(63):63ra94. doi: 10.1126/scitranslmed.3001375

Figure 4. Increased calreticulin expression confers a worse clinical prognosis in multiple human malignancies.

Figure 4

Stratification of clinical outcomes based on the level of expression of calreticulin mRNA is shown in previously described cohorts (50–55) of patients with diverse malignancies including neuroblastoma (A,B), superficial or invasive bladder cancer (C,D), and mantle cell lymphoma (E,F). Patients were divided into calreticulin high and low expression groups based on median calreticulin expression with Kaplan-Meier analyses of patient outcome shown. Hazard ratios (HR) and log-rank p values are shown for the relationship of outcomes to continuous expression of calreticulin using a univariate Cox regression model. HR, 95% confidence intervals, and log-rank p values for calreticulin expression as a dichotomous variable are shown in table S1. Description of clinical datasets is shown in table S1.